Cargando…

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children

INTRODUCTION: The REGAL (RSV Evidence – A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This seventh and final publication covers the past, pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simões, Eric A. F., Bont, Louis, Manzoni, Paolo, Fauroux, Brigitte, Paes, Bosco, Figueras-Aloy, Josep, Checchia, Paul A., Carbonell-Estrany, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840107/ https://www.ncbi.nlm.nih.gov/pubmed/29470837 http://dx.doi.org/10.1007/s40121-018-0188-z

Ejemplares similares

The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood
por: Fauroux, Brigitte, et al.
Publicado: (2017)

Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries
por: Bont, Louis, et al.
Publicado: (2016)

Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases
por: Manzoni, Paolo, et al.
Publicado: (2017)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease
por: Paes, Bosco, et al.
Publicado: (2016)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease
por: Checchia, Paul A., et al.
Publicado: (2017)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease
por: Figueras-Aloy, Josep, et al.
Publicado: (2016)

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study
por: Simões, Eric AF, et al.
Publicado: (2008)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017)

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age
por: Keary, Ian P., et al.
Publicado: (2023)

Introduction. RSV and RAD: possibilities for prevention? The link between respiratory syncytial virus and reactive airway disease
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2002)

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children
por: Simões, Eric A.F., et al.
Publicado: (2010)

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants
por: Blanken, Maarten O., et al.
Publicado: (2018)

The effects of varying protein and energy intakes on the growth and body composition of very low birth weight infants
por: Costa-Orvay, Juan Antonio, et al.
Publicado: (2011)

Trends in survival among extremely-low-birth-weight infants (less than 1000 g) without significant bronchopulmonary dysplasia
por: Botet, Francesc, et al.
Publicado: (2012)

Respiratory syncytial virus (RSV) disease – new data needed to guide future policy
por: Campbell, Harry, et al.
Publicado: (2015)

Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants—The SPRING Study
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2015)

Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS])
por: Carbonell‐Estrany, Xavier, et al.
Publicado: (2018)

Fail-Fast in Respiratory Syncytial Virus Vaccine Development
por: Besteman, Sjanna B., et al.
Publicado: (2019)

Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies
por: Lanari, M., et al.
Publicado: (2020)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step
por: Billard, Marie-Noëlle, et al.
Publicado: (2021)

Neutrophils in respiratory syncytial virus infection: A target for asthma prevention
por: Geerdink, Ruben J., et al.
Publicado: (2015)

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
por: Simões, Eric A. F., et al.
Publicado: (2015)

COVID-19 Lesson for Respiratory Syncytial Virus (RSV): Hygiene Works
por: Gastaldi, Andrea, et al.
Publicado: (2021)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2011)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
por: Papenburg, Jesse, et al.
Publicado: (2012)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Erratum to: Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2012)

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)
por: Wang, Daniel Y., et al.
Publicado: (2017)

Increased Risk of RSV Infection in Children with Down's Syndrome: Clinical Implementation of Prophylaxis in the European Union
por: van Beek, Dianne, et al.
Publicado: (2013)

Respiratory syncytial virus hospitalization and mortality: Systematic review and meta‐analysis
por: Stein, Renato T., et al.
Publicado: (2016)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Comparison of the Canadian vs. the international risk scoring tool for respiratory syncytial virus prophylaxis in moderate-to-late preterm infants
por: Butt, Michelle, et al.
Publicado: (2023)

Systemic Signature of the Lung Response to Respiratory Syncytial Virus Infection
por: Pennings, Jeroen L. A., et al.
Publicado: (2011)

The Association between Weather Conditions and Admissions to the Paediatric Intensive Care Unit for Respiratory Syncytial Virus Bronchiolitis
por: Linssen, Rosalie S., et al.
Publicado: (2021)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US
por: Zheng, Zhe, et al.
Publicado: (2021)

Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data
por: Rozenbaum, Mark H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_evhtdfrkjbuq4i1cfpmnpj92q0